Low Frequency Nonnucleoside Reverse‐Transcriptase Inhibitor–Resistant Variants Contribute to Failure of Efavirenz‐Containing Regimens in Treatment‐Experienced Patients
The Journal of Infectious Diseases2010Vol. 201(5), pp. 100126095936095–000
Citations Over TimeTop 10% of 2010 papers
Elias K. Halvas, Ann Wiegand, Valerie F. Boltz, Mary F. Kearney, Dwight V. Nissley, Michael Wantman, Scott M. Hammer, Sarah Palmer, Florin Vaida, John M. Coffin, John W. Mellors
Abstract
Minor NNRTI-resistant variants were more prevalent in NNRTI-experienced patients and were associated with reduced virologic response to efavirenz-containing multidrug regimens.
Related Papers
- → The pharmacokinetics of methadone in HIV‐positive patients receiving the non‐nucleoside reverse transcriptase inhibitor efavirenz(2001)153 cited
- → Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors(1999)70 cited
- → New Efavirenz Derivatives and 1,2,3-Triazolyl-phosphonates as Inhibitors of Reverse Transcriptase of HIV-1(2018)8 cited
- Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.(2006)
- → PIN17 TREATMENT PATTERNS AND DRUG TREATMENT COSTS ASSOCIATED WITH NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)-BASED ANTIRETROVIRAL THERAPY IN TREATMENT-NAÏVE HIV-1 INFECTED PATIENTS(2011)